EP1670817A4 - Uses of spatial configuration to modulate protein function - Google Patents

Uses of spatial configuration to modulate protein function

Info

Publication number
EP1670817A4
EP1670817A4 EP04782529A EP04782529A EP1670817A4 EP 1670817 A4 EP1670817 A4 EP 1670817A4 EP 04782529 A EP04782529 A EP 04782529A EP 04782529 A EP04782529 A EP 04782529A EP 1670817 A4 EP1670817 A4 EP 1670817A4
Authority
EP
European Patent Office
Prior art keywords
protein function
spatial configuration
modulate protein
modulate
spatial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04782529A
Other languages
German (de)
French (fr)
Other versions
EP1670817A2 (en
Inventor
Guangwen Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HUIYANGTECH (USA) Inc
HUIYANGTECH USA Inc
Original Assignee
HUIYANGTECH (USA) Inc
HUIYANGTECH USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1670817(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by HUIYANGTECH (USA) Inc, HUIYANGTECH USA Inc filed Critical HUIYANGTECH (USA) Inc
Publication of EP1670817A2 publication Critical patent/EP1670817A2/en
Publication of EP1670817A4 publication Critical patent/EP1670817A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
EP04782529A 2003-08-28 2004-08-26 Uses of spatial configuration to modulate protein function Ceased EP1670817A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US49844903P 2003-08-28 2003-08-28
US49892303P 2003-08-28 2003-08-28
US49878503P 2003-08-28 2003-08-28
IN280MU2004 2004-03-05
IN279MU2004 2004-03-05
PCT/US2004/028068 WO2005021777A2 (en) 2003-08-28 2004-08-26 Uses of spatial configuration to modulate protein function

Publications (2)

Publication Number Publication Date
EP1670817A2 EP1670817A2 (en) 2006-06-21
EP1670817A4 true EP1670817A4 (en) 2008-07-16

Family

ID=34280101

Family Applications (3)

Application Number Title Priority Date Filing Date
EP04809634.1A Active EP1663110B1 (en) 2003-08-28 2004-08-26 Uses of interferons with altered spatial structure
EP04782529A Ceased EP1670817A4 (en) 2003-08-28 2004-08-26 Uses of spatial configuration to modulate protein function
EP10193126.9A Active EP2325202B1 (en) 2003-08-28 2004-08-26 Uses of interferons with altered spatial structure

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP04809634.1A Active EP1663110B1 (en) 2003-08-28 2004-08-26 Uses of interferons with altered spatial structure

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10193126.9A Active EP2325202B1 (en) 2003-08-28 2004-08-26 Uses of interferons with altered spatial structure

Country Status (8)

Country Link
EP (3) EP1663110B1 (en)
JP (4) JP5663768B2 (en)
KR (2) KR20060130009A (en)
AU (2) AU2004279350B2 (en)
CA (2) CA2535902A1 (en)
HK (2) HK1091756A1 (en)
PL (2) PL2325202T3 (en)
WO (2) WO2005021777A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
CN1245215C (en) 2001-02-28 2006-03-15 四川省生物工程研究中心 Recombination high efficiency composite interferon used as hepatitis B surface antigen and e antigen inhibitor
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
EP1663110B1 (en) * 2003-08-28 2013-12-18 Superlab Far East Limited Uses of interferons with altered spatial structure
WO2006076014A2 (en) * 2004-04-30 2006-07-20 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Interferon-alpha constructs for use in the treatment of sars
US20080124302A1 (en) 2005-03-09 2008-05-29 Guangwen Wei Uses of Recombinant Super-Compound Interferons
CN102101886A (en) * 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 Variable-conformation recombinant interferon crystal, and three-dimensional structure and use thereof
TW201427681A (en) * 2013-01-07 2014-07-16 Superlab Far East Ltd A method for treating tumor by using recombinant interferon with changed spatial configuration
CN111363726A (en) 2018-12-26 2020-07-03 上海元宋生物技术有限公司 Oncolytic virus expressing interferon and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080958A1 (en) * 2001-02-28 2002-10-17 Sichuan Biotechnology Research Center Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
ATE328069T1 (en) * 1995-10-13 2006-06-15 Harvard College PHOSPHOPANTETHENYL TRANSFERASES AND USES THEREOF
US5874304A (en) * 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US20020043262A1 (en) * 2000-08-22 2002-04-18 Alan Langford Spray device
EP1355939A2 (en) * 2000-11-03 2003-10-29 Pestka Biomedical Laboratories, Inc. Interferons, uses and compositions related thereto
EP1663110B1 (en) * 2003-08-28 2013-12-18 Superlab Far East Limited Uses of interferons with altered spatial structure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080958A1 (en) * 2001-02-28 2002-10-17 Sichuan Biotechnology Research Center Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
EP1371373A1 (en) * 2001-02-28 2003-12-17 Sichuan Biotechnology Research Center Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMATO I: "Silent no longer", CHEMICAL AND ENGINEERING NEWS, vol. 85, no. 4, 22 January 2007 (2007-01-22), pages 38 - 40 *
ANONYMOUS: "Infergen", 30 November 1998 (1998-11-30) *

Also Published As

Publication number Publication date
AU2004279350A1 (en) 2005-04-21
KR20060133949A (en) 2006-12-27
CA2535902A1 (en) 2005-03-10
EP1663110B1 (en) 2013-12-18
JP5663768B2 (en) 2015-02-04
AU2004279350B2 (en) 2011-03-10
WO2005034853A3 (en) 2006-04-27
JP2011083292A (en) 2011-04-28
HK1091756A1 (en) 2007-01-26
EP1663110A4 (en) 2008-07-16
WO2005034853A2 (en) 2005-04-21
CA2535982A1 (en) 2005-04-21
AU2004269390A1 (en) 2005-03-10
WO2005021777A3 (en) 2005-05-12
KR20060130009A (en) 2006-12-18
PL2325202T3 (en) 2015-03-31
CA2535982C (en) 2016-11-29
WO2005021777A2 (en) 2005-03-10
JP5709800B2 (en) 2015-04-30
EP2325202B1 (en) 2014-10-22
JP2007516214A (en) 2007-06-21
EP2325202A1 (en) 2011-05-25
EP1670817A2 (en) 2006-06-21
PL1663110T3 (en) 2014-07-31
JP2012162567A (en) 2012-08-30
EP1663110A2 (en) 2006-06-07
HK1158231A1 (en) 2012-09-14
JP2007503812A (en) 2007-03-01

Similar Documents

Publication Publication Date Title
GB2408407B (en) Smart translation of generic configurations
IL173440A0 (en) Novel formulation of ropinirole
GB0202633D0 (en) Stabilization of protein preparations
EP1607081A4 (en) Cosmetic preparation
HK1092703A1 (en) Stabilized formulations of phosphatidylserine
HK1080376A1 (en) Cosmetic preparation
EP1632213A4 (en) Cosmetic preparation
SI1587542T1 (en) Use of anti-cd100 antibodies
AU2003255982A1 (en) Preparation of microcapsules
EP1684790A4 (en) Homogeneous preparations of chimeric proteins
AU2003252072A8 (en) Modulation of protein kinase c-iota expression
HK1090065A1 (en) Preparation of somatostatin peptides
AU2003279841A1 (en) Uses of human zven antagonists
EP1670817A4 (en) Uses of spatial configuration to modulate protein function
HK1080448A1 (en) Preparation of prostamides
AU2003226899A8 (en) Human diabetes-mediating proteins
AU2003282338A8 (en) Determination of protein function
GB0218332D0 (en) Preparation of type pneumocytes
EP1512745A4 (en) Pigment protein
AU2003250819A1 (en) Use of compounds that stimulate cgmp
AU2003246614A8 (en) Novel use of lipopeptide preparations
AU2003286273A8 (en) Decorrelation of signals
PL371427A1 (en) New uses of substituted aminoalkanephosphonic acids
AU2003217174A8 (en) Novel variants of rankl protein
EP1534756A4 (en) Expression of hydrophobic proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060324

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1091846

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20080617

17Q First examination report despatched

Effective date: 20081127

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20110628

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1091846

Country of ref document: HK